News

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Viral transduction of CD34+ cells is a promising approach for treating inherited disorders such as sickle cell disease, ß-thalassemia, or primary immunodeficiencies. The CliniMACS Prodigy® Hematopoietic Stem Cell Engineering (HSCE) System allows for manufacturing of gene-engineered hematopoietic stem cells (HSCs) from human CD34+ cells.

The CliniMACS Prodigy Cell Manufacturing Platform automates the generation of gene-engineered HSCs by viral transduction in a functionally closed system. All steps are automated and manufacturing takes place in sterile and single-use tubing sets, ensuring highly reproducible and standardized manufacturing processes.

In-process control and quality control (IPC/QC) are required for consistent cell manufacturing. Integrated sampling pouches on the CliniMACS Tubing Sets allow for controls to be collected at any time during, and at the end of the cell manufacturing process. Miltenyi Biotec provides complete solutions with its MACS Flow Cytometers and a wide portfolio of MACS IVD Antibodies.

News

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

A prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...

Learn more